c-met-in-1 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T10653	c-met-IN-1		c-Met/HGFR
	c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.		c-Met/HGFR
T8409	SYN1143	RON-IN-1,AMG-1	c-Met/HGFR
	SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.		c-Met/HGFR
T4332	c-Kit-IN-1	PDGFR inhibitor 1,DCC-2618	c-Met/HGFR , c-Kit
	c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).		c-Met/HGFR , c-Kit
T13194	CSF1R-IN-2		c-Fms , c-Met/HGFR , Src
	CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).		c-Fms , c-Met/HGFR , Src
T11162	EGFR-IN-8		EGFR , c-Met/HGFR
	EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.		EGFR , c-Met/HGFR
T80874	VEGFR-2/c-Met-IN-1		VEGFR
	VEGFR-2/c-Met-IN-1 is a dual inhibitor targeting VEGFR-2 and c-Met with respective IC50 values of 138 nM and 74 nM, demonstrating antitumor activity [1].		VEGFR
T72407	c-Met/MEK1/Flt-3-IN-1
	Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-depende...
T63544	RIPK3-IN-1
	RIPK3-IN-1 is a type II RIPK3DFG-out site inhibitor (IC50: 9.1 nM) that inhibits RIPK1 (IC50: 5.5 μM) and RIPK2 (IC50>10 μM). RIPK3-IN-1 is a c-Met kinase inhibitor (IC50: 1.1 μM).
T2668	JNK-IN-8	JNK Inhibitor XVI	JNK , c-Kit
	JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM). The selectivity is higher 10-fold than MNK2, Fms and no inhibition of Met, c-Kit, PDGFRβ in A375 cell line.		JNK , c-Kit
T4349	Sitravatinib	MG516,MGCD516	Discoidin Domain Receptor (DDR) , VEGFR , FLT , Trk receptor , TAM Receptor , c-Kit , Ephrin Receptor
	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
T5S1331	Herbacetin		c-Met/HGFR , Akt
	1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation.		c-Met/HGFR , Akt
T64080	c-Met-IN-12
	c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to ...
T79142	c-Met-IN-17		c-Met/HGFR
	c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]		c-Met/HGFR
T78934	c-Met-IN-18		c-Met/HGFR
	C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancer...		c-Met/HGFR
T64185	TAM&Met-IN-1
	TAM&Met-IN-1 is a potent inhibitor of TAM and c-Met, acting on AXL (IC50: 6.1 nM), MER (IC50: 13.2 nM) and TYRO3 (IC50: 21.6 nM). TAM&Met-IN-1 can be used in anticancer studies.
T72978	c-Met-IN-16
	c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .
T79715	c-Met-IN-19		c-Met/HGFR
	c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0...		c-Met/HGFR
T63901	Axl-IN-8
	Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).
T80885	Val-Cit-amide-Cbz-N(Me)-Maytansine
	Val-Cit-amide-Cbz-N(Me)-Maytansine is a molecule that functions both as an antibody and a bispecific antigen-binding entity, targeting the hepatocyte growth factor receptor c-Met (MET), and is used in the formulation of ...
T83557	(3S,4S)-Tivantinib	ARQ 198,(3S,4S)-ARQ 197
	(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in the pathogenesis of non-small cell lung cancer (NSCLC) [1].